2,4-二氯-4-硝基二苯基醚 | 22544-07-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2,4-二氯-4-硝基二苯基醚
• 中文别名: 3-氯-4-(4-氯苯氧基)硝基苯
• 英文名称: 4-(4'-chlorophenoxy)-3-chloronitrobenzene
• 英文别名: 3-chloro-4-(4-chlorophenoxy)nitrobenzene；3‑chloro‑4‑(4'‑chlorophenoxy)nitrobenzene；(2-chloro-4-nitro-phenyl)-(4-chloro-phenyl)-ether；(2-Chlor-4-nitro-phenyl)-(4-chlor-phenyl)-aether；2-chloro-1-(4-chlorophenoxy)-4-nitrobenzene；2,4'-dichloro-4-nitrodiphenyl ether
• CAS: 22544-07-6
• 化学式: C₁₂H₇Cl₂NO₃
• mdl: MFCD00204156
• 分子量: 284.098
• InChiKey: RTCVXHVOOYCYNA-UHFFFAOYSA-N

物化性质

• 熔点：
  105-109 °C(lit.)
• 沸点：
  351.6±32.0 °C(Predicted)
• 密度：
  1.451±0.06 g/cm3(Predicted)
• 稳定性/保质期：
  如果按照规格使用和储存，则不会分解，未有已知危险发生。避免与强氧化剂接触。

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  55
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 安全说明：
  S22,S24/25
• WGK Germany：
  3
• 海关编码：
  2909309090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  请将药品存放在密闭、阴凉干燥的地方，并保持良好通风。

反应信息

• 作为反应物：
  描述：

  2,4-二氯-4-硝基二苯基醚 在 盐酸 、 tin(ll) chloride 、 N,N'-二异丙基碳二亚胺 作用下， 以 溶剂黄146 、 N,N-二甲基甲酰胺 为溶剂， 反应 6.0h， 生成 N-<3-chloro-4-(4'-chlorophenoxy)phenyl>cyanoacetamide
  参考文献：
  名称：

  Synthesis and biological activity of a series of diaryl-substituted .alpha.-cyano-.beta.-hydroxypropenamides, a new class of anthelmintic agents

  摘要：

  A series of alpha-cyano-beta-hydroxypropenamides was prepared and tested for anthelmintic activity. Alpha-cyano-beta-hydroxy hydroxy-N-[4-(trifluoromethyl)phenyl]-3-[4-(trifluoromethyl)phenyl]propenamide (1) showed good activity against the nematode Nematospirodes dubius in a mixed parasite infection in mice; several of the analogues were also effective against the cestode Hymenolepis nana. In sheep trials, 1 caused 100% reduction of the hematophagous nematode Haemonchus contortus after a single dose of 20 mg/kg but did not show satisfactory control of Trichostrongylus colubriformis or Ostertagia circumcincta. Against the liver fluke Fasciola hepatica, 1 suppressed egg production but only temporarily, suggesting that the adult flukes were not eliminated. Mechanism of action studies on 1 using Ascaris mitochondria showed it to be an uncoupler of oxidative phosphorylation.

  DOI：

  10.1021/jm00115a020
• 作为产物：
  描述：

  sodium 4-chlorophenolate 、 2,5-二氯硝基苯 生成 2,4-二氯-4-硝基二苯基醚
  参考文献：
  名称：

  Process for preparing nitrodiphenyl (thio) ethers

  摘要：

  对于在乙醚氧或硫上与硝基团处于邻位或对位的硝基二苯基（硫）醚，可以通过在液氨中使用卤硝基苯酮和碱金属（硫）酚在压力下进行反应，并在温度从-30摄氏度到+140摄氏度进行反应，完成反应后分离氨气来制备。

  公开号：

  US05382686A1

文献信息

• Structural development of N-(4-phenoxyphenyl)benzamide derivatives as novel SPAK inhibitors blocking WNK kinase signaling
  作者：Shinya Fujii、Eriko Kikuchi、Yuko Watanabe、Honoka Suzuyama、Mari Ishigami-Yuasa、Takayasu Mori、Kiyoshi Isobe、Shinichi Uchida、Hiroyuki Kagechika

  DOI：10.1016/j.bmcl.2020.127408

  日期：2020.9

  structural development of N-(4-phenoxyphenyl)benzamide derivatives as novel SPAK (STE20/SPS1-related proline/alanine-rich kinase) inhibitors. Abnormal activation of the signal cascade of with-no-lysine kinase (WNK) with OSR1 (oxidative stress-responsive kinase 1)/SPAK and NCC (NaCl cotransporter) results in characteristic salt-sensitive hypertension, and therefore inhibitors of the WNK-OSR1/SPAK-NCC

  我们在这里报告的N-（4-苯氧基苯基）苯甲酰胺衍生物作为新型SPAK（STE20 / SPS1相关脯氨酸/富含丙氨酸的激酶）抑制剂的结构发展。具有OSR1（氧化应激反应激酶1）/ SPAK和NCC（NaCl协同转运蛋白）的无赖氨酸激酶（WNK）信号级联的异常激活会导致特征性的盐敏感性高血压，因此是WNK-OSR1的抑制剂/ SPAK-NCC级联是抗高血压药物的候选药物。根据前导化合物2的结构，我们研究了N-（4-苯氧基苯基）苯甲酰胺衍生物的SAR ，并开发了作为有效SPAK抑制剂的化合物20l。化合物20l是新型抗高血压药的有希望的候选物。
• Anthelmintically active benzenepropanamide derivatives
  申请人：Syntex (U.S.A.) Inc.

  公开号：US05034410A1

  公开（公告）日：1991-07-23

  This invention is directed to a method for treating helminthiasis in an animal which method comprises administering to an animal in need thereof an anthelmintically effective amount of a compound of the Formula (I): ##STR1## wherein Z is oxygen or sulfur; R.sup.1 is hydrogen or lower alkyl; and R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are independently hydrogen, halo, lower haloalkyl, lower alkoxy, lower haloalkoxy, nitro, cyano, halophenoxy, haloalkylphenoxy, thiocyano or isothiocyano, provided that R.sup.2 and R.sup.3 cannot simultaneously be hydrogen and that R.sup.4 and R.sup.5 cannot simultaneously be hydrogen; or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions formulated therewith. This invention is also directed to novel anthelmintically active benzenepropanamides of Formula (I) wherein Z is oxygen.

  这项发明涉及一种用于治疗动物蛔虫病的方法，该方法包括向需要治疗的动物施用公式（I）化合物的驱虫有效量：##STR1## 其中Z为氧或硫；R.sup.1为氢或较低的烷基；R.sup.2、R.sup.3、R.sup.4和R.sup.5独立地为氢、卤素、较低的卤代烷基、较低的烷氧基、较低的卤代烷氧基、硝基、氰基、卤苯氧基、卤代烷基苯氧基、硫氰基或异硫氰基，但要求R.sup.2和R.sup.3不能同时为氢，R.sup.4和R.sup.5也不能同时为氢；或其药学上可接受的盐，并且配制的药物组合物。这项发明还涉及新型具有驱虫活性的苯丙酰胺类化合物的公式（I），其中Z为氧。
• ANTI-VIRAL COMPOUNDS
  申请人：Rockway W. Todd

  公开号：US20070232645A1

  公开（公告）日：2007-10-04

  Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, co-formulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for the syntheses of such compounds, and methods of using such compounds for the treatment of HCV or other viral infections.

  本发明揭示了有效抑制丙型肝炎病毒（“HCV”）或其他病毒复制的化合物。本发明还涉及包含这种化合物的组合物、与其他抗病毒或治疗剂一起配方或共同管理这种化合物的组合物、用于合成这种化合物的过程和中间体，以及使用这种化合物治疗HCV或其他病毒感染的方法。
• Anti-viral compounds
  申请人：Abbott Laboratories

  公开号：US07763731B2

  公开（公告）日：2010-07-27

  Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, co-formulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for the syntheses of such compounds, and methods of using such compounds for the treatment of HCV or other viral infections.

  本发明揭示了一种有效抑制丙型肝炎病毒（“HCV”）或其他病毒复制的化合物。该发明还涉及包含这种化合物的组合物、与其他抗病毒或治疗剂共同配方或共同管理这种化合物的组合物、用于合成这种化合物的过程和中间体，以及使用这种化合物治疗HCV或其他病毒感染的方法。
• Anti-Viral Compounds
  申请人：Rockway Todd W.

  公开号：US20100256139A1

  公开（公告）日：2010-10-07

  Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, co-formulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for the syntheses of such compounds, and methods of using such compounds for the treatment of HCV or other viral infections.

  本发明揭示了一些有效抑制丙型肝炎病毒（“HCV”）或其他病毒复制的化合物。本发明还涉及包含这些化合物的组合物，这些化合物与其他抗病毒或治疗剂的联合制剂或联合给药，用于合成这些化合物的过程和中间体，以及使用这些化合物治疗HCV或其他病毒感染的方法。